[go: up one dir, main page]

JOP20170192A1 - داي نوكليوتيد حلقي - Google Patents

داي نوكليوتيد حلقي

Info

Publication number
JOP20170192A1
JOP20170192A1 JOP/2017/0192A JOP20170192A JOP20170192A1 JO P20170192 A1 JOP20170192 A1 JO P20170192A1 JO P20170192 A JOP20170192 A JO P20170192A JO P20170192 A1 JOP20170192 A1 JO P20170192A1
Authority
JO
Jordan
Prior art keywords
cyclic dinucleotide
present disclosure
sting
compound
prophylaxis
Prior art date
Application number
JOP/2017/0192A
Other languages
English (en)
Inventor
Shiokawa Zenyu
Mochizuki Michiyo
Tawaraishi Taisuke
Shibuya Akito
Okabe Atsutoshi
Seki Tomohiro
Oda Tsuneo
Sasaki Yusuke
Okaniwa Masanori
Nakada Yoshihisa
Kato Taisuke
Nakagawa Yasuo
Seto Masaki
HIDAKA Kosuke
MURATA Shumpei
Wada Yasufumi
Yoshikawa Masato
YOSHITOMI Yayoi
Scott Freeze Brian
Tominari Yusuke
Saitoh Morihisa
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Priority claimed from JP2017107216A external-priority patent/JP2018090562A/ja
Publication of JOP20170192A1 publication Critical patent/JOP20170192A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

يوفر الكشف الحالي مركب ذي نشاط مساعد STING، المتوقع أن يكون مفيد كعامل للوقاية من أو علاج أمراض مرتبطة بـ STING. يتعلق الكشف الحالي بمركب تم التعبير عنه بواسطة الصيغة (I): حيث يكون كل رمز كما تم الوصف في المواصفات، أو ملح منه.
JOP/2017/0192A 2016-12-01 2016-12-01 داي نوكليوتيد حلقي JOP20170192A1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2016234553 2016-12-01
JP2017107216A JP2018090562A (ja) 2016-12-01 2017-05-30 環状ジヌクレオチド
US201762589300P 2017-11-21 2017-11-21

Publications (1)

Publication Number Publication Date
JOP20170192A1 true JOP20170192A1 (ar) 2019-01-30

Family

ID=66179467

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2017/0192A JOP20170192A1 (ar) 2016-12-01 2016-12-01 داي نوكليوتيد حلقي

Country Status (30)

Country Link
US (4) US10980825B2 (ar)
EP (2) EP3868384A1 (ar)
JP (2) JP6633255B1 (ar)
KR (1) KR102640802B1 (ar)
CN (1) CN110325543B (ar)
AU (1) AU2017370004B2 (ar)
CA (1) CA3045762A1 (ar)
CL (1) CL2019001485A1 (ar)
CO (1) CO2019007032A2 (ar)
CY (1) CY1124196T1 (ar)
DK (1) DK3512861T3 (ar)
EC (1) ECSP19046507A (ar)
ES (1) ES2866948T3 (ar)
HR (1) HRP20210726T1 (ar)
HU (1) HUE054450T2 (ar)
IL (1) IL267020B (ar)
JO (1) JOP20170192A1 (ar)
LT (1) LT3512861T (ar)
MA (1) MA46245A (ar)
MX (1) MX2019006397A (ar)
MY (1) MY190460A (ar)
PE (1) PE20210255A1 (ar)
PH (1) PH12019501222A1 (ar)
PL (1) PL3512861T3 (ar)
PT (1) PT3512861T (ar)
RS (1) RS61818B1 (ar)
SI (1) SI3512861T1 (ar)
UA (1) UA126390C2 (ar)
WO (1) WO2018100558A2 (ar)
ZA (1) ZA201904311B (ar)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11453697B1 (en) 2015-08-13 2022-09-27 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
EP3429596B1 (en) 2016-03-18 2022-08-31 Immune Sensor, LLC Cyclic di-nucleotide compounds and methods of use
WO2018009648A1 (en) 2016-07-06 2018-01-11 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
US10662416B2 (en) 2016-10-14 2020-05-26 Precision Biosciences, Inc. Engineered meganucleases specific for recognition sequences in the hepatitis B virus genome
JOP20170192A1 (ar) 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co داي نوكليوتيد حلقي
WO2018118665A1 (en) * 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Cyclic dinucleotide sting agonists for cancer treatment
US11492367B2 (en) * 2017-01-27 2022-11-08 Janssen Biotech, Inc. Cyclic dinucleotides as sting agonists
JP7591348B2 (ja) 2017-02-21 2024-11-28 ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム インターフェロン遺伝子刺激因子依存性シグナル伝達のアゴニストとしての環状ジヌクレオチド
EP3692048A4 (en) 2017-08-30 2021-10-20 Beijing Xuanyi Pharmasciences Co., Ltd. CYCLIC DI-NUCLEOTIDES AS STIMULATORS OF INTERFERON GENE MODULATORS
US11638716B2 (en) 2017-08-31 2023-05-02 F-star Therapeutics, Inc. Compounds, compositions, and methods for the treatment of disease
WO2019051488A1 (en) 2017-09-11 2019-03-14 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE
WO2019051489A1 (en) 2017-09-11 2019-03-14 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE
WO2019084060A1 (en) 2017-10-24 2019-05-02 Silverback Therapeutics, Inc. CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS
TW201922263A (zh) 2017-11-10 2019-06-16 日商武田藥品工業股份有限公司 干擾素基因刺激蛋白之調節化合物，及製造和使用方法
US11203610B2 (en) 2017-12-20 2021-12-21 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
US11685761B2 (en) 2017-12-20 2023-06-27 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
CN111566120B (zh) 2017-12-20 2023-09-29 捷克共和国有机化学与生物化学研究所 活化sting转接蛋白的具有膦酸酯键的3’3’环状二核苷酸
EP3505188A1 (en) 2017-12-29 2019-07-03 Invivogen Pro-cyclic dinucleotide conjugates for cytokine induction
US10836769B2 (en) 2018-02-26 2020-11-17 Gilead Sciences, Inc. Substituted pyrrolizine compounds and uses thereof
IL277344B2 (en) 2018-03-23 2024-05-01 Codiak Biosciences Inc Extracellular vesicles comprising sting-agonist
US10870691B2 (en) 2018-04-05 2020-12-22 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis B virus protein X
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TW201945388A (zh) 2018-04-12 2019-12-01 美商精密生物科學公司 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶
WO2019211799A1 (en) 2018-05-03 2019-11-07 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
CA3106110A1 (en) 2018-07-10 2020-01-16 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
EP3841112A1 (en) 2018-08-24 2021-06-30 Codiak BioSciences, Inc. Extracellular vesicles targeting dendritic cells and uses thereof
SMT202500141T1 (it) 2018-09-06 2025-05-12 Daiichi Sankyo Co Ltd Coniugati farmaco-anticorpo di derivati dinucleotidici ciclici
SG11202101980VA (en) 2018-09-12 2021-03-30 Silverback Therapeutics Inc Methods and composition for the treatment of disease with immune stimulatory conjugates
EP3854799B1 (en) 2018-09-21 2024-07-17 Shanghai de Novo Pharmatech Co., Ltd. Cyclic dinucleotide analogue, pharmaceutical composition thereof, and application
EP3856258B1 (en) 2018-09-27 2024-07-31 Pierre Fabre Medicament Sulfomaleimide-based linkers and corresponding conjugates
US11110106B2 (en) 2018-10-29 2021-09-07 Venenum Biodesign, LLC Sting agonists for treating bladder cancer and solid tumors
US11161864B2 (en) 2018-10-29 2021-11-02 Venenum Biodesign, LLC Sting agonists
EP4371987B9 (en) 2018-10-31 2025-11-26 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
KR102658602B1 (ko) 2018-10-31 2024-04-19 길리애드 사이언시즈, 인코포레이티드 Hpk1 억제 활성을 갖는 치환된 6-아자벤즈이미다졸 화합물
US20220143061A1 (en) 2019-03-07 2022-05-12 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
CN113543851B (zh) 2019-03-07 2025-03-18 捷克共和国有机化学与生物化学研究所 2’3’-环二核苷酸及其前药
EP3935065A1 (en) 2019-03-07 2022-01-12 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
US12233356B2 (en) 2019-03-21 2025-02-25 Lonza Sales Ag Process for preparing extracellular vesicles
SG11202109587TA (en) 2019-03-21 2021-10-28 Codiak Biosciences Inc Extracellular vesicle conjugates and uses thereof
CA3133311A1 (en) 2019-03-21 2020-09-24 Codiak Biosciences, Inc. Extracellular vesicles for vaccine delivery
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
JP7621974B2 (ja) 2019-05-09 2025-01-27 アリゴス セラピューティクス インコーポレイテッド Ｓｔｉｎｇモジュレータとしての修飾環状ジヌクレオシド化合物
CN119770674A (zh) 2019-05-10 2025-04-08 武田药品工业株式会社 抗体药物缀合物
WO2020237025A1 (en) 2019-05-23 2020-11-26 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
WO2020263830A1 (en) 2019-06-25 2020-12-30 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use
EP3994158A1 (en) 2019-07-03 2022-05-11 Codiak BioSciences, Inc. Extracellular vesicles targeting t cells and uses thereof
EP3993834A1 (en) 2019-07-05 2022-05-11 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
EP3996718A1 (en) * 2019-07-09 2022-05-18 Takeda Pharmaceutical Company Limited Administration of sting agonist and checkpoint inhibitors
CN117838878A (zh) * 2019-07-19 2024-04-09 免疫传感器治疗股份有限公司 抗体-sting激动剂缀合物及其在免疫疗法中的用途
EP4017476A1 (en) 2019-08-19 2022-06-29 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
WO2021046426A1 (en) * 2019-09-06 2021-03-11 Sperovie Biosciences, Inc. Cyclic dinucleotide sting agonists tethered to a pd-1 or ctla-4 antibodies
JP2022549328A (ja) 2019-09-25 2022-11-24 コディアック バイオサイエンシーズ， インコーポレイテッド 細胞外小胞組成物
EP4034276A1 (en) 2019-09-25 2022-08-03 Codiak BioSciences, Inc. Methods of producing extracellular vesicles
CA3152488A1 (en) 2019-09-25 2021-04-01 Codiak Biosciences, Inc. Combination therapy using extracellular vesicles
EP4034247A1 (en) 2019-09-25 2022-08-03 Codiak BioSciences, Inc. Sting agonist comprising exosomes for treating neuroimmunological disorders
CA3149557A1 (en) 2019-09-30 2021-04-08 Scott J. Balsitis Hbv vaccines and methods treating hbv
CA3151322A1 (en) 2019-10-01 2021-04-08 Silverback Therapeutics, Inc. Combination therapy with immune stimulatory conjugates
WO2021113765A1 (en) 2019-12-06 2021-06-10 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
WO2021168274A1 (en) 2020-02-21 2021-08-26 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
CA3168368A1 (en) 2020-03-06 2021-09-10 Masayuki Ishizaki Antibody-drug conjugate including novel cyclic dinucleotide derivative
EP4117717A1 (en) 2020-03-13 2023-01-18 Codiak BioSciences, Inc. Extracellular vesicles for treating neurological disorders
AR121620A1 (es) 2020-03-20 2022-06-22 Gilead Sciences Inc Profármacos de nucleósidos 4’-c-sustituidos-2-halo-2’-deoxiadenosina y métodos de preparación y uso de los mismos
JP2023518414A (ja) 2020-03-20 2023-05-01 コディアック バイオサイエンシーズ， インコーポレイテッド 治療のための細胞外小胞
US20230141284A1 (en) 2020-04-10 2023-05-11 Ono Pharmaceutical Co., Ltd. Cancer therapeutic method
WO2021216572A1 (en) 2020-04-20 2021-10-28 Massachusetts Institute Of Technology Lipid compositions for delivery of sting agonist compounds and uses thereof
WO2021237100A1 (en) 2020-05-21 2021-11-25 Codiak Biosciences, Inc. Methods of targeting extracellular vesicles to lung
WO2021261996A2 (en) * 2020-06-24 2021-12-30 Sapreme Technologies B.V. Nhs-based saponin conjugates
AU2021295292A1 (en) * 2020-06-24 2023-02-16 Sapreme Technologies B.V. Saponin derivatives for use in medicine
KR20230047361A (ko) 2020-07-01 2023-04-07 아르스 파마슈티컬스 인크. 항-asgr1 항체 접합체 및 이의 용도
ES3054072T3 (en) 2020-08-07 2026-01-29 Gilead Sciences Inc Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use
US20230256109A1 (en) 2020-08-07 2023-08-17 Tambo, Inc. Trans-Cyclooctene Bioorthogonal Agents and Uses in Cancer and Immunotherapy
CA3191395A1 (en) 2020-09-02 2022-03-10 Daiichi Sankyo Company, Limited Novel endo-.beta.-n-acetylglucosaminidase
CA3191593A1 (en) * 2020-09-08 2022-03-17 Jinming Gao Polyvalent sting activating compositions and uses thereof
EP4217087A2 (en) 2020-09-23 2023-08-02 Codiak BioSciences, Inc. Process for preparing extracellular vesicles
WO2022066883A1 (en) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Extracellular vesicles comprising kras antigens and uses thereof
WO2022066928A2 (en) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Process for preparing extracellular vesicles
WO2022066898A2 (en) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Methods of producing extracellular vesicles
KR102558127B1 (ko) * 2020-10-23 2023-07-24 아주대학교산학협력단 아릴피페라진 유도체를 유효성분으로 포함하는 인터페론 유전자 자극제 조성물
IL302390A (en) 2020-11-09 2023-06-01 Takeda Pharmaceuticals Co Drug antibody conjugates
MX2023005695A (es) * 2020-11-18 2023-05-29 Takeda Pharmaceuticals Co Administracion de agonista de sting, inhibidores de puntos de control y radiacion.
CN116490244A (zh) * 2020-11-18 2023-07-25 武田药品工业株式会社 Sting激动剂、检查点抑制剂和辐射的施用
JP2024518558A (ja) 2021-05-13 2024-05-01 ギリアード サイエンシーズ， インコーポレイテッド ＴＬＲ８調節化合物と抗ＨＢＶ ｓｉＲＮＡ治療薬との組合せ
WO2022245671A1 (en) 2021-05-18 2022-11-24 Gilead Sciences, Inc. Methods of using flt3l-fc fusion proteins
EP4359413A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
US11932634B2 (en) 2021-06-23 2024-03-19 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
US11976072B2 (en) 2021-06-23 2024-05-07 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
WO2022271659A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
EP4137499A1 (en) 2021-08-17 2023-02-22 Ustav organicke chemie a biochemie AV CR, v.v.i. 7-substituted 7-deazaadenine-containing 2,3 -cyclic dinucleotides
WO2023056468A1 (en) 2021-09-30 2023-04-06 Codiak Biosciences, Inc. Extracellular vesicle comprising cholesterol tagged sting-agonist
IL315341A (en) 2022-03-02 2024-10-01 Daiichi Sankyo Co Ltd METHOD FOR PRODUCING Fc-CONTAINING MOLECULE
EP4558511A2 (en) 2022-07-21 2025-05-28 Firefly Bio, Inc. Glucocorticoid receptor agonists and conjugates thereof
WO2024048490A1 (ja) 2022-08-29 2024-03-07 第一三共株式会社 変異Ｆｃ領域を含む抗体薬物コンジュゲート
KR20250129814A (ko) * 2023-01-18 2025-08-29 타이리간드 바이오사이언스 (상하이) 리미티드 항체-약물 접합체 및 이의 용도
WO2025240246A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
WO2025240242A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
US20250345390A1 (en) 2024-05-13 2025-11-13 Gilead Sciences, Inc. Combination therapies
US20250345389A1 (en) 2024-05-13 2025-11-13 Gilead Sciences, Inc. Combination therapies

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL90359A0 (en) 1988-05-26 1989-12-15 University Patents Inc Nucleoside and polynucleotide thiophosphoramidite and phosphorodithioate compounds and their production
GB2257704B (en) 1991-07-18 1995-03-01 Erba Carlo Spa Cyclic oligonucleotides phosphorothioates
EP1539233B1 (en) 2001-07-12 2011-04-27 FOOTE, Jefferson Super humanized antibodies
EP2660322A3 (en) 2003-04-17 2013-11-13 Alnylam Pharmaceuticals Inc. Modified iRNA agents
WO2005005450A1 (ja) 2003-07-15 2005-01-20 Mitsui Chemicals, Inc. 環状ビスジヌクレオシドの合成方法
US8367716B2 (en) 2003-07-28 2013-02-05 Karaolis David K R Method for attentuating virulence of microbial pathogens and for inhibiting microbial biofilm formation
JP4887284B2 (ja) 2004-03-15 2012-02-29 デイビッド・ケイ・アール・カラオリス 癌細胞の増殖を阻害するための、または癌細胞のアポトーシスを増大させるための方法
US7592326B2 (en) 2004-03-15 2009-09-22 Karaolis David K R Method for stimulating the immune, inflammatory or neuroprotective response
EP1768998A2 (en) 2004-04-27 2007-04-04 Alnylam Pharmaceuticals Inc. Single-stranded and double-stranded oligonucleotides comprising a 2-arylpropyl moiety
WO2006045041A2 (en) 2004-10-18 2006-04-27 The Board Of Trustees Of The Leland Stanford Junior University Methods for microbial biofilm destruction and interference with microbial cellular physiology
EP1782826A1 (en) 2005-11-08 2007-05-09 GBF Gesellschaft für Biotechnologische Forschung mbH PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions
US8076303B2 (en) * 2005-12-13 2011-12-13 Spring Bank Pharmaceuticals, Inc. Nucleotide and oligonucleotide prodrugs
US8034921B2 (en) 2006-11-21 2011-10-11 Alnylam Pharmaceuticals, Inc. IRNA agents targeting CCR5 expressing cells and uses thereof
WO2009133560A1 (en) 2008-04-29 2009-11-05 Smart Assays Non-hydrolyzable and permeable cyclic bis-[nucleotide monophosphate] derivatives and uses thereof
WO2011003025A1 (en) 2009-07-01 2011-01-06 Rutgers, The State University Of New Jersey Synthesis of cyclic diguanosine monophosphate and thiophosphate analogs thereof
KR101885383B1 (ko) 2009-07-06 2018-08-03 웨이브 라이프 사이언시스 리미티드 신규한 핵산 프로드러그 및 그의 사용 방법
CA3031851C (en) 2009-10-23 2020-07-07 Amgen British Columbia Anti-gcc antibody molecules and related compositions and methods
US8450293B2 (en) 2010-08-10 2013-05-28 Rutgers, The State University Of New Jersey Synthesis and characterization of C8 analogs of c-di-GMP
RU2678807C2 (ru) 2011-11-18 2019-02-01 Элнилэм Фармасьютикалз, Инк. СРЕДСТВА ДЛЯ РНКи, КОМПОЗИЦИИ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, АССОЦИИРОВАННЫХ С ТРАНСТИРЕТИНОМ (TTR)
US9156915B2 (en) 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
CN104507538B (zh) 2012-06-08 2018-04-06 艾杜罗生物科技公司 癌症免疫疗法的组合物和方法
US9090646B2 (en) 2012-12-05 2015-07-28 Rutgers, The State University Of New Jersey Biotinylated compounds
KR20150095668A (ko) 2012-12-13 2015-08-21 아두로 바이오테크, 인코포레이티드 규정된 입체화학을 갖는 환식 퓨린 다이뉴클레오타이드를 포함하는 조성물, 그리고 이의 제조 방법 및 용도
CN110201155A (zh) 2012-12-19 2019-09-06 得克萨斯州立大学董事会 哺乳动物的环二核苷酸信号通路的药物靶向
WO2014109256A1 (ja) 2013-01-09 2014-07-17 国立大学法人東北大学 トリアゾール連結型環状ジヌクレオチド類縁体
JP2016524593A (ja) 2013-04-29 2016-08-18 メモリアル スローン−ケタリング キャンサー センター セカンドメッセンジャーのシグナル伝達を変えるための組成物及び方法
JP2016518140A (ja) 2013-05-03 2016-06-23 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｉ型インターフェロンの環状ジヌクレオチド誘導法
US9549944B2 (en) * 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
EP2996472B1 (en) 2013-05-18 2019-03-27 Aduro Biotech, Inc. Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling
US9724408B2 (en) * 2013-05-18 2017-08-08 Aduro Biotech, Inc. Compositions and methods for activating stimulator of interferon gene-dependent signalling
WO2015017652A1 (en) 2013-07-31 2015-02-05 Memorial Sloan-Kettering Cancer Center Sting crystals and modulators
WO2015077354A1 (en) 2013-11-19 2015-05-28 The University Of Chicago Use of sting agonist as cancer treatment
CA2931146C (en) 2013-11-22 2022-06-28 Brock University Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants
MX2016015928A (es) 2014-06-04 2017-03-20 Glaxosmithkline Ip Dev Ltd Dinucleotidos ciclicos como moduladores de sting.
EP3233191A1 (en) 2014-12-16 2017-10-25 Invivogen Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment
WO2016096174A1 (en) * 2014-12-16 2016-06-23 Invivogen Fluorinated cyclic dinucleotides for cytokine induction
CN107109133B (zh) * 2014-12-22 2021-04-13 巴斯夫欧洲公司 化学机械抛光(cmp)组合物在抛光包含钴和/或钴合金的基材中的用途
GB201501462D0 (en) * 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
JP6692826B2 (ja) 2015-03-10 2020-05-13 アドゥロ バイオテック，インク． 「インターフェロン遺伝子刺激因子」依存性シグナル伝達の活性化のための組成物及び方法
FR3037784B1 (fr) * 2015-06-29 2017-12-15 Gexfix Sa Dispositif de fixation externe dynamique d'osteosynthese
WO2017011444A1 (en) 2015-07-13 2017-01-19 The Wistar Institute Of Anatomy And Biology Methods and compositions for treating b cell cancers
TW201717968A (zh) 2015-07-14 2017-06-01 春季銀行製藥公司 誘導ｒｉｇ－ｉ和其他模式辨識受體之化合物及組成物
WO2017019896A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to pd-1
UA123701C2 (uk) * 2015-08-13 2021-05-19 Мерк Шарп І Доум Корп. Циклічні динуклеотидні сполуки як агоністи sting
US10906930B2 (en) 2015-10-28 2021-02-02 Chinook Therapeutics, Inc. Compositions and methods for activating “stimulator of interferon gene”-dependent signalling
US20170146519A1 (en) 2015-11-20 2017-05-25 Oregon Health & Science University Sting agonists and methods of selecting sting agonists
ES2863225T3 (es) 2015-12-03 2021-10-11 Glaxosmithkline Ip Dev Ltd Dinucleótidos cíclicos purinos como moduladores del sting
WO2017100305A2 (en) 2015-12-07 2017-06-15 Opi Vi - Ip Holdco Llc Composition of antibody construct-agonist conjugates and methods of use thereof
WO2017106740A1 (en) 2015-12-16 2017-06-22 Aduro Biotech, Inc. Methods for identifying inhibitors of "stimulator of interferon gene"-dependent interferon production
EP3402801B1 (en) 2016-01-11 2025-08-06 Innate Tumor Immunity, Inc. Cyclic dinucleotides for treating conditions associated with sting activity such as cancer
US10723756B2 (en) 2016-01-11 2020-07-28 Innate Tumor Immunity Inc. Cyclic dinucleotides for treating conditions associated with STING activity such as cancer
EP3429596B1 (en) * 2016-03-18 2022-08-31 Immune Sensor, LLC Cyclic di-nucleotide compounds and methods of use
EP3432868B1 (en) 2016-03-23 2020-12-16 Academia Sinica Thin-shell polymeric nanoparticles and uses thereof
WO2017175156A1 (en) 2016-04-07 2017-10-12 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
CR20200045A (es) 2016-04-07 2020-03-11 Glaxosmithkline Ip Dev Ltd AMIDAS HETEROCÍCLICAS ÚTILES COMO MODULADORES DE PROTEÍNAS (Divisional 2018-0472)
WO2017186711A1 (en) 2016-04-25 2017-11-02 Invivogen Novel complexes of immunostimulatory compounds, and uses thereof
EP3452492A1 (en) 2016-05-05 2019-03-13 Novartis AG Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase
WO2018009466A1 (en) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
WO2018009648A1 (en) 2016-07-06 2018-01-11 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
TW201803886A (zh) 2016-07-06 2018-02-01 史貝羅威生物科學有限公司 化合物、組合物及用於治療疾病之方法
EP3484504A4 (en) 2016-07-15 2020-07-29 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS OF TREATMENT OF DISEASE
WO2018013887A1 (en) 2016-07-15 2018-01-18 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
US20190345191A1 (en) 2016-08-31 2019-11-14 Innate Tumor Immunity, Inc. Cyclic dinucleotide analogs for treating conditions associated with sting (stimulator of interferon genes) activity
US10537590B2 (en) 2016-09-30 2020-01-21 Boehringer Ingelheim International Gmbh Cyclic dinucleotide compounds
UA125223C2 (uk) 2016-10-04 2022-02-02 Мерк Шарп І Доум Корп. СПОЛУКИ БЕНЗО[b]ТІОФЕНУ ЯК АГОНІСТИ STING
US11001605B2 (en) 2016-10-07 2021-05-11 Biolog Life Science Institute Gmbh & Co. Kg Cyclic dinucleotides containing benzimidazole, method for the production of same, and use of same to activate stimulator of interferon genes (sting)-dependent signaling pathways
JOP20170188A1 (ar) 2016-11-25 2019-01-30 Janssen Biotech Inc ثنائي النوكليوتيدات الحلقية كمنبهات ستينغ (sting)
JP2018090562A (ja) * 2016-12-01 2018-06-14 武田薬品工業株式会社 環状ジヌクレオチド
JOP20170192A1 (ar) 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co داي نوكليوتيد حلقي
US20190328762A1 (en) 2016-12-20 2019-10-31 Merck Sharp & Dohme Corp. Combinations of pd-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment
WO2018118665A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Cyclic dinucleotide sting agonists for cancer treatment
WO2018119117A1 (en) 2016-12-22 2018-06-28 The Regents Of The University Of California Methods of producing cyclic dinucleotides
US20190336615A1 (en) 2017-01-27 2019-11-07 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
US11492367B2 (en) 2017-01-27 2022-11-08 Janssen Biotech, Inc. Cyclic dinucleotides as sting agonists
ES2891326T3 (es) 2017-01-27 2022-01-27 Janssen Biotech Inc Dinucleótidos cíclicos como agonistas de la STING
US20200055883A1 (en) 2017-02-17 2020-02-20 Eisai R&D Management Co., Ltd. Cyclic di-nucleotides derivative for the treatment of cancer
JP7591348B2 (ja) 2017-02-21 2024-11-28 ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム インターフェロン遺伝子刺激因子依存性シグナル伝達のアゴニストとしての環状ジヌクレオチド
CN106667914B (zh) 2017-03-13 2022-02-01 杭州星鳌生物科技有限公司 靶向脂质体-环二核苷酸的组成、制备方法及其在抗肿瘤中的应用
JOP20190218A1 (ar) 2017-03-22 2019-09-22 Boehringer Ingelheim Int مركبات ثنائية النيوكليوتيدات حلقية معدلة
WO2018198084A1 (en) 2017-04-27 2018-11-01 Lupin Limited Cyclic di-nucleotide compounds with tricyclic nucleobases
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
AR113224A1 (es) 2017-04-28 2020-02-19 Novartis Ag Conjugados de anticuerpo que comprenden un agonista de sting
EP3692048A4 (en) 2017-08-30 2021-10-20 Beijing Xuanyi Pharmasciences Co., Ltd. CYCLIC DI-NUCLEOTIDES AS STIMULATORS OF INTERFERON GENE MODULATORS
US11667663B2 (en) 2017-08-31 2023-06-06 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
ES2904317T3 (es) 2017-08-31 2022-04-04 Bristol Myers Squibb Co Dinucleótidos cíclicos como agentes anticancerosos
CA3075751A1 (en) 2017-09-15 2019-03-21 Aduro Biotech, Inc. Pyrazolopyrimidinone compounds and uses thereof
IL302390A (en) 2020-11-09 2023-06-01 Takeda Pharmaceuticals Co Drug antibody conjugates

Also Published As

Publication number Publication date
US20240066047A1 (en) 2024-02-29
CL2019001485A1 (es) 2020-01-10
IL267020A (en) 2019-07-31
LT3512861T (lt) 2021-05-25
JP2020055860A (ja) 2020-04-09
MX2019006397A (es) 2019-08-14
EP3868384A1 (en) 2021-08-25
KR102640802B1 (ko) 2024-02-26
ZA201904311B (en) 2022-04-28
PH12019501222A1 (en) 2019-12-02
EP3512861A2 (en) 2019-07-24
CO2019007032A2 (es) 2019-10-21
CA3045762A1 (en) 2018-06-07
AU2017370004B2 (en) 2022-03-10
ECSP19046507A (es) 2019-09-30
US20210106607A1 (en) 2021-04-15
WO2018100558A9 (en) 2019-05-09
CN110325543A (zh) 2019-10-11
RS61818B1 (sr) 2021-06-30
DK3512861T3 (da) 2021-05-03
CN110325543B (zh) 2023-03-31
WO2018100558A8 (en) 2019-06-20
JP6633255B1 (ja) 2020-01-22
CY1124196T1 (el) 2022-05-27
ES2866948T3 (es) 2021-10-20
US20190192549A1 (en) 2019-06-27
KR20190113768A (ko) 2019-10-08
EP3512861B1 (en) 2021-02-17
WO2018100558A3 (en) 2018-07-19
SI3512861T1 (sl) 2021-08-31
WO2018100558A2 (en) 2018-06-07
PT3512861T (pt) 2021-04-29
HUE054450T2 (hu) 2021-09-28
BR112019011120A2 (pt) 2019-10-01
US20210137962A9 (en) 2021-05-13
US12171777B2 (en) 2024-12-24
MY190460A (en) 2022-04-21
US20250205270A1 (en) 2025-06-26
US11666594B2 (en) 2023-06-06
UA126390C2 (uk) 2022-09-28
JP7229907B2 (ja) 2023-02-28
PE20210255A1 (es) 2021-02-10
HRP20210726T1 (hr) 2021-10-01
MA46245A (fr) 2019-07-24
US10980825B2 (en) 2021-04-20
IL267020B (en) 2022-01-01
PL3512861T3 (pl) 2021-09-20
NZ754737A (en) 2025-08-29
AU2017370004A1 (en) 2019-07-11
JP2020504085A (ja) 2020-02-06

Similar Documents

Publication Publication Date Title
JOP20170192A1 (ar) داي نوكليوتيد حلقي
ZA202001717B (en) Compounds, salts thereof and methods for treatment of diseases
JOP20200225A1 (ar) مشتق كوينولين عالي النقاء وطريقة لإنتاجه
SG11201901061QA (en) Heterocyclic compound
PH12016500225B1 (en) Novel quinoline-substituted compound
PH12017502363A1 (en) Brk inhibitory compound
TN2014000122A1 (en) 1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases
PH12016501582A1 (en) Fused heterocyclic compound
PH12016501614A1 (en) Heterocyclic compound
EA201390794A1 (ru) Бициклическое соединение
PH12020550585A1 (en) Sting modulator compounds, and methods of making and using
EA201990833A1 (ru) Соединение пиридина
BR112017011422A2 (pt) compostos de ácido isoazol hidro¬xâmico como inibidores de lpxc
PH12019502248A1 (en) Ip6k inhibitors
TN2017000097A1 (en) Heterocyclic compound
PH12016502130B1 (en) Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect
EA201692063A1 (ru) Спиросоединения мочевины в качестве противовирусных соединений против rsv
UY37502A (es) Dinucleótido cíclico
MX2021003481A (es) Compuesto heterociclico.
MY174153A (en) Processes for the preparation of pyrimidinylcyclopentane compounds
EA201401277A1 (ru) Соединения метантиона, обладающие противовирусной активностью
GEP20156399B (en) Microbiocidal heterocycles
EA201991315A1 (ru) Циклические динуклеотиды в качестве агонистов sting (стимулятор генов интерферона)
TN2013000230A1 (en) Bicyclic compound
MX2016009250A (es) Nuevos imidazoles para el tratamiento y profilaxis de la infeccion por virus sincicial respiratorio.